Health Catalyst (HCAT) Competitors

Health Catalyst (NASDAQ:HCAT) and Integral Ad Science (NASDAQ:IAS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, community ranking, earnings, valuation, risk and media sentiment.

Is HCAT or IAS more profitable?

Integral Ad Science has a net margin of 6.39% compared to Health Catalyst's net margin of -26.20%. Integral Ad Science's return on equity of 3.47% beat Health Catalyst's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Health Catalyst	-26.20%	-7.51%	-3.72%
Integral Ad Science	6.39%	3.47%	2.83%

Which has more volatility & risk, HCAT or IAS?

Health Catalyst has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Comparatively, Integral Ad Science has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.

Which has better earnings and valuation, HCAT or IAS?

Integral Ad Science has higher revenue and earnings than Health Catalyst. Health Catalyst is trading at a lower price-to-earnings ratio than Integral Ad Science, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Catalyst	$306.58M	0.86	-$118.15M	-$1.15	-3.26
Integral Ad Science	$530.10M	1.98	$7.24M	$0.23	27.87

Do analysts prefer HCAT or IAS?

Health Catalyst currently has a consensus target price of $8.36, indicating a potential upside of 123.03%. Integral Ad Science has a consensus target price of $14.45, indicating a potential upside of 125.43%. Given Integral Ad Science's higher possible upside, analysts plainly believe Integral Ad Science is more favorable than Health Catalyst.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Catalyst	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70
Integral Ad Science	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55

Do insiders & institutionals have more ownership in HCAT or IAS?

85.0% of Health Catalyst shares are owned by institutional investors. Comparatively, 95.8% of Integral Ad Science shares are owned by institutional investors. 2.5% of Health Catalyst shares are owned by insiders. Comparatively, 2.0% of Integral Ad Science shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Does the MarketBeat Community prefer HCAT or IAS?

Health Catalyst received 113 more outperform votes than Integral Ad Science when rated by MarketBeat users. Likewise, 67.21% of users gave Health Catalyst an outperform vote while only 51.52% of users gave Integral Ad Science an outperform vote.

Company	Underperform	Outperform
Health Catalyst	Outperform Votes 164 67.21%	Underperform Votes 80 32.79%
Integral Ad Science	Outperform Votes 51 51.52%	Underperform Votes 48 48.48%

Does the media favor HCAT or IAS?

In the previous week, Health Catalyst had 1 more articles in the media than Integral Ad Science. MarketBeat recorded 10 mentions for Health Catalyst and 9 mentions for Integral Ad Science. Integral Ad Science's average media sentiment score of 0.56 beat Health Catalyst's score of 0.39 indicating that Integral Ad Science is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Health Catalyst	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Integral Ad Science	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Integral Ad Science beats Health Catalyst on 12 of the 18 factors compared between the two stocks.